NCT06795009View on ClinicalTrials.gov

Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

November 30, 2029

Study Completion Date

April 30, 2035

Conditions
Uterine CancerEndometrial Cancer
Interventions
DRUG

Zanzalintinib

Taken by mouth.

DRUG

Paclitaxel

175 mg\^m2 intravenous over 3 hours.

Trial Locations (4)

63110

RECRUITING

Washington University School of Medicine, St Louis

73104

NOT_YET_RECRUITING

University of Oklahoma, Oklahoma City

87106

NOT_YET_RECRUITING

University of New Mexico, Albuquerque

94143

NOT_YET_RECRUITING

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Exelixis
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Exelixis

INDUSTRY

lead

Washington University School of Medicine

OTHER